Literature DB >> 9811382

Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.

M Ohali1, H Shalev, M Schlesinger, Y Katz, L Kachko, R Carmi, S Sofer, D Landau.   

Abstract

We describe the clinical course, complement components, and pathological findings of 10 infants with autosomal recessive hemolytic uremic syndrome (HUS). All patients were members of one extended highly inbred Bedouin kindred. The median age of presentation was 2 weeks (range 1-20 weeks). Eight patients died, 2 patients are alive, on dialysis. Renal biopsies revealed thrombotic microangiopathy with a predominant early arteriolar involvement and subsequent development of ischemic glomerular changes. Immunofluorescence was positive for C3 in glomeruli. All patients had low complement components levels during and between relapses, and in some this was evident soon after birth and prior to the onset of symptoms. This deficiency could not be normalized by repeated plasma transfusions. Biosynthetic labelling of patients' fibroblasts demonstrated normal rates of C3 protein synthesis. Serum factor H levels were greatly decreased or absent in 4 patients tested and moderately decreased in 15 of 23 healthy unaffected siblings and patients. This defect may cause complement activation and consumption, possibly at the endothelial cell level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811382     DOI: 10.1007/s004670050515

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

1.  The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion.

Authors:  Guido A Hegasy; Tamara Manuelian; Kolbjorn Hogasen; Johan H Jansen; Peter F Zipfel
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  What's new in haemolytic uraemic syndrome?

Authors:  Sally Johnson; C Mark Taylor
Journal:  Eur J Pediatr       Date:  2008-06-25       Impact factor: 3.183

3.  Hemolytic uremic syndrome due to homozygous factor H deficiency.

Authors:  Sidharth Kumar Sethi; Dragon-Durey Marie-Agnes; Neelam Thaker; Pankaj Hari; Arvind Bagga
Journal:  Clin Exp Nephrol       Date:  2009-07-01       Impact factor: 2.801

4.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

5.  Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency.

Authors:  Katell Michaux; Justine Bacchetta; Etienne Javouhey; Pierre Cochat; Véronique Frémaux-Bacchi; Anne-Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

6.  Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome.

Authors:  L Ying; Y Katz; M Schlesinger; R Carmi; H Shalev; N Haider; G Beck; V C Sheffield; D Landau
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 7.  Genetic kidney diseases in the pediatric population of southern Israel.

Authors:  Gal Finer; Hanna Shalev; Daniel Landau
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

8.  Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality.

Authors:  Angela Gerber; Antje H Kirchhoff-Moradpour; Silke Obieglo; Matthias Brandis; Michael Kirschfink; Peter F Zipfel; Judith A Goodship; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 9.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

Review 10.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.